fbpx

molecules of the month

VT-104

oral pan-TEAD auto-palmitoylation inhibitor

tumor regression at 3 mg/kg QD

from 160k compound cell-based HTS

Mol. Cancer. Ther., Apr. 13, 2021

Vivace Therapeutics, San Mateo, CA

VT-104
1 min read

The Vivace Therapeutics pan-TEAD transcription factor inhibitor, VT-104, binds to a lipid pocket on TEAD, preventing its auto-palmitoylation, similar to a previously highlighted TEAD inhibitor. In contrast to previously published TEAD inhibitors, VT104 has high oral bioavailability (78%) and a long half-life (24 h) in mice, and demonstrates in vivo tumor regression at a low daily dose of 3 mg/kg. Interestingly in the paper, the authors refer to anNF2 mutant tumor being “lost” due to the difficulty in growing the tumors - these things happen in real life drug discovery.


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: